Clearpoint Neuro Inc Stock Price, News & Analysis

ClearPoint Neuro reports a 16% revenue increase to $3.7 million in Q4 2020, with full-year revenues totaling $12.8 million, up 14% from 2019. Notably, biologics and drug delivery revenues surged by 109% to $5.0 million, while functional neurosurgery revenues declined by 12% to $6.3 million due to COVID-19 challenges. The company's gross margin improved to 71%, attributed to higher service revenue. Despite a solid year, ClearPoint refrains from forecasting for 2021, citing persistent COVID-related disruptions in elective procedure volumes.

ClearPoint Neuro (Nasdaq: CLPT) has successfully closed a public stock offering, selling 2,127,660 shares, including 1,850,140 at $23.50 each and 277,520 following underwriters' options at $22.09. The net proceeds are approximately $46.8 million, which will support product development, R&D activities, and general corporate purposes. CEO Joe Burnett highlighted the strategic use of this capital to enhance the company’s capabilities in neuro-based therapies. B. Riley Securities managed the offering, with shares sold under an effective SEC registration statement.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) will release its financial results for Q4 and the full year 2020 on March 4, 2021, after market close. Investors can join a live call at 4:30 p.m. ET to discuss the results. ClearPoint specializes in neurosurgery navigation and drug delivery systems, currently having FDA clearance for its products, with installations across over 60 sites. The company is engaged with multiple biologics firms, supporting various stages of clinical trials. Forward-looking statements highlight potential impacts, including COVID-19, on future revenues and market acceptance.

ClearPoint Neuro (Nasdaq: CLPT) announced the pricing of a public offering of 1,850,140 shares of common stock at $23.50 per share, with an option for underwriters to purchase an additional 277,520 shares. The offering is set to close on February 23, 2021. Proceeds will fund product development and research, as well as general corporate purposes. B. Riley Securities is leading the offering, following SEC approval on January 29, 2021.

ClearPoint Neuro (Nasdaq: CLPT) has announced a proposed underwritten public offering of its common stock, with all shares being offered by the Company. This offering includes a 30-day option for underwriters to purchase additional shares, totaling up to 15% of the offering size. The offering is subject to market conditions, and there's no guarantee regarding its completion or terms. B. Riley Securities is the book-running manager, while Lake Street Capital Markets acts as the co-manager. The SEC has declared effective a shelf registration statement related to the offering.

ClearPoint Neuro (CLPT) announced a worldwide license and research agreement with Philips to develop the ‘Maestro™’ Brain Model, set for launch in 2022. This collaboration aims to enhance various applications in drug delivery, deep brain stimulation, laser ablation, and biopsies, enabling precise treatment paths and safer procedures. Philips' Brain Model technology, developed over 10 years, offers accurate assessments backed by extensive research. ClearPoint’s products are FDA cleared and used in over 60 clinical sites across the U.S., Canada, and Europe, supporting a diverse range of neurological therapies.

ClearPoint Neuro has announced a partnership with Blackrock Microsystems to develop innovative products in the neurosurgery market. This collaboration is set to tap into a combined addressable market exceeding $100 million. The first product, the Microelectric Recording (MER) platform, is expected to launch in 2023, followed by advanced biopsy needles and other neural electrodes. This strategic alliance combines ClearPoint's navigation expertise and Blackrock's precision electrode technology, aiming to enhance patient outcomes in neurosurgery.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the appointment of R. John Fletcher as Chairman of the Board, succeeding Kimble L. Jenkins, who retired to focus on his CEO role at OrthoSouth. Joe Burnett, CEO of ClearPoint, praised Jenkins for his contributions in growing the company. Fletcher, recognized for his leadership during Spectranetics' acquisition by Philips for $2.2 billion, aims to guide ClearPoint in its next growth phase. The company continues to advance its neurosurgery solutions, including FDA-cleared products for complex neurological disorders.

ClearPoint Neuro (Nasdaq: CLPT) announced the appointment of Ernesto Salegio, PhD, as Vice President, Segment Leader of Translational and Pre-Clinical Research, starting March 1, 2021. Dr. Salegio has over 19 years of experience in translational neuroscience, specializing in gene therapy delivery. He will enhance ClearPoint’s Biologics and Drug Delivery team, established in 2020, aimed at supporting pharmaceutical partners with pre-clinical services. ClearPoint aims to provide comprehensive medical device solutions for gene and stem cell therapies to improve patient care.